RSS Feed      Printer Friendly      Email It     PDF Version    Bookmark del.icio.us    Diggs

    SAN DIEGO, CA, December 08, 2009 /24-7PressRelease/ -- Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. Eidogen-Sertanty will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modeling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.

"We're extremely pleased to have licensed the TIP technology to the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief Executive Officer. "We very much look forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level."

Eidogen-Sertanty contact:

Steve Muskal
760-651-2885
pr@eidogen-sertanty.com

About Eidogen-Sertanty

Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty's unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services, please visit www.eidogen-sertanty.com.


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com

# # #

Press Release Keywords:

• fda, eidogen, target informatics, tip, adverse drug reactions, fda, drug-protein interactions, padre, nctr

Read more Press Releases from Steven Muskal:

• Eidogen-Sertanty to Release Oncology Database
• Eidogen-Sertanty Collaborates on Educational Apps
• Eidogen-Sertanty Enhances iProtein iPad App
• Eidogen-Sertanty Partners with Molecular Materials Informatics to Enhance MobileReagents iPhone App
• Eidogen-Sertanty Releases MobileReagents iPhone App
• Eidogen-Sertanty Releases iProtein - Target Informatics on the iPad
• Eidogen-Sertanty Offers Academic Version of Kinase Database
• Eidogen-Sertanty Releases iKinasePro - an iPad App in the Cloud
• Eidogen-Sertanty Releases iKinase iPhone Application

Other Press Release Headlines:

• FracRock International Announces Closing of Series A Preferred Stock Offering
• Spine Injury Information Many Doctors Don't Explain
• Snoring Solution for Travelers
• Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety
• Dr. Hartmut Derendorf to Discuss PK/PD-based Drug Development in Rosa's World-Wide Webinar Series, "Impact of Modeling & Simulation in Drug Development"
• Washington University Implements Digisonics PACS and Structured Reporting System for Pediatric Cardiology
• How Young is Too Young? Plastic Surgeon Speaks Out
• GiiResearch.com: Full-Field Digital Mammography (FFDM) Equipment Market to Reach $1.3 Billion in 2017
• Prisoners With Harsh Crack Cocaine Convictions to Be Released Early
• Portable Vehicle Barrier (PVB) Increases Market Share as Stadiums, Police and Private Companies Rush to Buy